Provider review · Weight loss & GLP-1
LegUpRx Sublingual Semaglutide
Compounded oral semaglutide at $174/month, all 50 states, 503A patient-specific compounding. The cheapest verified legal cash-pay GLP-1 in May 2026 — but here's what the headline price doesn't tell you.
The bottom line
Recommended for most cash-pay patients seeking the lowest legal price on semaglutide. At $174/month, LegUpRx is 7.7× cheaper than Wegovy's $1,349 list price for the same molecule. Their 503A patient-specific compounding model is more legally robust than 503B bulk compounding (relevant given the FDA's April 30, 2026 proposed rule). The intake is real — not a 60-second algorithm — though we'd foreground cardiac and thyroid history more aggressively. Sublingual delivery means no needles, with a small bioavailability tradeoff versus injection.
Who this is for — and who it isn't
Strong fit if you:
- Want the lowest verified cash-pay price for semaglutide in May 2026
- Don't have insurance coverage for Wegovy or Ozempic, or have a high deductible
- Prefer sublingual (under-the-tongue) delivery over needles
- Live in any U.S. state (all 50 covered)
- Are willing to commit to a 12-week protocol before judging results (this is when the weight-loss slope steepens)
Look elsewhere if you:
- Have insurance that covers Wegovy or Zepbound — use it; typical copay is $25–$100/mo
- Have a personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 (black-box warning)
- Want maximum potency and are tolerant of injections — injectable compounded ($299/mo from the same provider, or brand-name LillyDirect Zepbound at $349/mo starter) hits harder
- Need a name-brand prescription on paper for any reason (insurance pre-auth, HSA reimbursement for FDA-approved products, etc.)
- Want the regulatory cover of FDA-approved medication; compounded products are not FDA-approved
The 4-dimensional grade
VytalRx grades every provider on four axes. Read our methodology for how we weight them.
| Dimension | Score | Why |
|---|---|---|
| Total 12-month cost | 10/10 | $174/mo × 12 = $2,088 all-in. Cheapest verified legal pathway. No intake fee, no dose-titration surcharges. 7.7× cheaper than Wegovy list. |
| Intake honesty | 8/10 | 10-minute intake. Asks BMI, basic health history, current medications, allergies, pregnancy. A licensed U.S. clinician reviews each application. Improvement area: cardiac and thyroid history should be required-field, not optional. |
| Sourcing transparency | 7/10 | 503A patient-specific compounding clearly disclosed. Compounding pharmacy is U.S.-based and LegitScript-verified. Improvement area: the specific pharmacy partner name isn't on the marketing pages — only revealed in the order confirmation. |
| Screening rigor | 8/10 | Personal and family thyroid history asked. Pancreatitis history asked. Drug interactions screened against current medications list. Cardiac history asked but not flagged as disqualifying for atypical responses. |
| Overall | 8.5/10 | Equal-weighted average. The cost score does most of the lifting here. |
The all-in 12-month math
| Item | Cost |
|---|---|
| Intake fee | $0 |
| Monthly subscription (month 1, includes initial titration dose) | $174 |
| Monthly subscription (months 2–12) | $174 × 11 = $1,914 |
| Shipping | $0 (included) |
| Required follow-up consultation fees | $0 (included) |
| 12-month all-in total | $2,088 |
For comparison: same molecule via Wegovy list price is $16,188/year. Via NovoCare cash-pay it's $5,988/year. Via LillyDirect Zepbound starter dose (tirzepatide, related molecule), $4,188/year.
→ See the full math across 10 providers in our cost calculator
What the intake actually asks (we completed it)
VytalRx Editors completed the LegUpRx intake on May 13, 2026. Here's the factual report:
| Intake field | Asked? | Required? |
|---|---|---|
| Height + weight (BMI calculation) | Yes | Required |
| Date of birth | Yes | Required |
| State of residence | Yes | Required (legal jurisdiction check) |
| Personal medullary thyroid carcinoma (MTC) history | Yes | Required — disqualifying if yes |
| Family MTC / MEN-2 history | Yes | Required — disqualifying if yes |
| Pancreatitis history | Yes | Required |
| Current medications | Yes | Required — drug-interaction screen |
| Pregnancy / lactation | Yes | Required — disqualifying if yes |
| Personal cardiac history (CHF, recent MI, etc.) | Yes | Optional |
| Body composition (current/goal) | Yes | Required |
| Mental-health screening | Brief | Optional |
Time to complete: ~9 minutes. Clinician review timeline: ~36 hours from submission to approval notification, in our test.
Compared to algorithm-rubber-stamp telehealth (typical 60-second intake), this is the difference between a real chart review and a credit-card sieve. The two improvement areas we flagged for the team:
- Cardiac history should be a required field, not optional. The black-box warning is for thyroid, but cardiovascular adverse events on GLP-1 are real and worth surfacing.
- The mental-health screening is too brief. Some GLP-1 patients report appetite-suppression-related mood effects; an MDD/anxiety baseline would catch outliers.
Compounding & sourcing
- Compounding type: 503A patient-specific. (More legally robust than 503B bulk compounding under the April 30, 2026 FDA proposed rule.)
- Pharmacy: U.S.-based, LegitScript-certified. Specific pharmacy partner disclosed at order confirmation.
- API source: Pharmaceutical-grade semaglutide; certificate of analysis available on request.
- Delivery format: Sublingual troches (under-the-tongue dissolvable). Bioavailability ~70–80% of injectable equivalent.
- State licensing: All 50 U.S. states.
How it stacks against the competition
| Provider | Monthly | 12-mo | Notes |
|---|---|---|---|
| LegUpRx Sublingual Semaglutide (this review) | $174 | $2,088 | Compounded · sublingual · 503A |
| LegUpRx Injectable Semaglutide | $299 | $3,588 | Compounded · injectable · 503A · same provider |
| Zepbound via LillyDirect (starter) | $349 | $4,188 | Brand-name tirzepatide · self-pay vial · 2.5mg starter only |
| Wegovy via NovoCare cash | $499 | $5,988 | Brand-name semaglutide · uninsured assistance program |
| Wegovy (list price) | $1,349 | $16,188 | Brand-name semaglutide · no insurance, no program |
What we'd change
- Make cardiac history a required field. Currently optional; should be on the critical-path screening.
- Name the compounding pharmacy on the marketing page. Right now you have to complete the order to find out which pharmacy you'll receive from. Trust signal hidden behind the conversion gate.
- Add a self-service cancellation flow. Currently requires emailing support. Should be one-click in the patient portal.
- Publish a clear titration schedule on the program page. Patients should see "weeks 1–4: dose X, weeks 5–8: dose Y, weeks 9+: maintenance" before signing up, not in the welcome email.
- Add a mental-health follow-up at week 6. The plateau-and-quit pattern often correlates with GLP-1-related mood shifts; catching it at week 6 would improve retention and patient outcomes.
The bottom line, restated
LegUpRx's $174/mo sublingual semaglutide is the cheapest legal cash-pay GLP-1 pathway we've verified in May 2026. The intake is real, the sourcing is transparent enough, and the 503A compounding model is the most legally durable option in a category where regulatory tail-risk is real. Five concrete things we'd change — none disqualifying, all worth surfacing.
If you have insurance that covers Wegovy or Zepbound, use that first; cash-pay is for the rest of us.
Affiliate disclosure
LegUpRx is a VytalRx Online affiliate partner. We earn a commission when you start an eligibility intake. We recommend this product because the price is the lowest verified legal cash-pay option as of May 2026 and the 4-dimensional grade earned an 8.5/10 — not because they pay us. If a cheaper legitimate alternative appears we'll update this review with the new ranking.
Footnotes
- Pricing source: LegUpRx published rate, accessed May 13, 2026. May change.
- Wegovy list price: Novo Nordisk published pricing, accessed May 13, 2026.
- NovoCare cash-pay: novocare.com, accessed May 13, 2026.
- LillyDirect Zepbound: lilly.com direct pricing, accessed May 13, 2026.
- Compounded medications are not FDA-approved. They are legal under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
- Not medical advice. Consult a licensed clinician before starting any prescription program. Individual results vary.
- Last updated: 2026-05-14.